Home › Chronic Kidney Disease › Ohio › Cleveland
Chronic Kidney Disease clinical trials in Cleveland, OH
5 studies for Chronic Kidney Disease are looking for participants at sites in and around Cleveland (within about 30 miles). Open a study to see who can join and how to contact the study team.
A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)
RecruitingPhase 3
- Cleveland Clinic, Cleveland
A Study of Praliciguat in Participants With Focal Segmental Glomerulosclerosis (FSGS)
RecruitingPhase 2
- Investigator Site #20, Cleveland
Monocytes in Subjects With Type 1 Diabetes and Chronic Kidney Disease
RecruitingObservational study
- Cleveland Clinic, Cleveland
Kidney Precision Medicine Project
RecruitingObservational study
- Cleveland Clinic, Cleveland
A Trial of Etelcalcetide in Pediatric Participants With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis
RecruitingPhase 3
- Cleveland Clinic Foundation, Cleveland
About Chronic Kidney Disease
If your kidneys are damaged and can't filter blood easily, then you may suffer from chronic kidney disease (CKD). Read about the treatments available
More about Chronic Kidney Disease on MedlinePlus
Chronic Kidney Disease trials in other cities
- New York City, NY16 studies
- Houston, TX15 studies
- Boston, MA15 studies
- Dallas, TX15 studies
- Philadelphia, PA15 studies
- Chicago, IL13 studies
- Orlando, FL11 studies
- Atlanta, GA10 studies
- Kansas City, MO9 studies
- Durham, NC9 studies
- Albuquerque, NM8 studies
- Washington, DC8 studies
Other studies in Cleveland
- Non-Small Cell Lung Cancer44 studies
- Cancer (all types)37 studies
- Breast Cancer35 studies
- Prostate Cancer34 studies
- Heart Failure33 studies
- Metastatic Cancer30 studies
- Ovarian Cancer28 studies
- Lung Cancer26 studies
- Colorectal Cancer24 studies
- Cardiovascular Disease22 studies
- Endometrial Cancer21 studies
- Acute Myeloid Leukemia20 studies
From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.